返回
Castle Biosciences Inc（CSTL）價格
CSTL 股價走勢圖
CSTL 收益
Castle Biosciences Inc
$42.84
-0.46%
$-0.19
收盤價：Jan 27, 16:00:00 GMT-5
$42.84
0%
$0
盤前：Jan 28, 07:10:02 GMT-5
關鍵數據
前收市價
$43.04
開盤價
$43
當日範圍
$42.39 - $43.2
52週區間
$14.59 - $44.28
交易量
353.2K
平均成交量
431.1K
每股盈餘 (TTM)
-0.45
股息收益率
--
市值
$1.2B
什麼是 CSTL？
Castle Biosciences, Inc.is a molecular diagnostics company offering innovative test solutions to aid clinicians in the diagnosis and treatment of dermatologic cancers, barrett’s esophagus, uveal melanoma, and in the treatment of mental health conditions. The company is headquartered in Friendswood, Texas and currently employs 761 full-time employees. The company went IPO on 2019-07-25. The firm offers five commercially available proprietary multi-analyte assays with algorithmic analysis (MAAA) tests for use in the fields of dermatology, gastroenterology and ophthalmology. The company also offers a proprietary pharmacogenomic (PGx) test to guide optimal drug treatment for patients diagnosed with depression, anxiety and other mental health conditions. Its products include DecisionDx-Melanoma, DecisionDx-SCC, MyPath Melanoma, TissueCypher, IDgenetix, and DecisionDx-UM. DecisionDx-SCC is its proprietary gene expression profile (GEP) test for use in patients with cutaneous squamous cell carcinoma (SCC). The company also focused on chronic acid reflux related diseases, including esophageal cancer.